A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors CASI Pharmaceuticals
- 07 Sep 2017 According to a CASI Pharmaceuticals media release, it is anticipated that the data from this study will be submitted to a medical conference for presentation in 2018.
- 23 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.